Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDivislaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Divis Lab, Torrent Pharma good buys: Daljeet Singh Kohli

      Daljeet Singh Kohli of India Nivesh Securities is of the view that Divis Laboratories and Torrent Pharmaceuticals are still good buys.

    • Buy Divis Labs on dips, target Rs 2400-2450: Amit Gupta

      Amit Gupta of ICICIdirect recommends buying Divis Labs on dips for target of Rs 2400 and Rs 2450.

    • Buy Divis Lab, Wockhardt; add Aurobindo Pharma: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Divis Laboratories and Wockhardt and adding Aurobindo Pharma.

    • Bull's Eye: Buy Titan, PTC India, Exide, Rel Infra, Sun TV

      Gaurav Ratnaparkhi of Sharekhan advises buying Sun TV with a target of Rs 339.

    • Buy Strides Arcolab, Divis Labs on dips: Kunal Bothra

      Kunal Bothra of LKP Securities is of the view that one can buy Strides Arcolab and Divis Laboratories on dips.

    • Go long in Divis Laboratories: Manas Jaiswal

      Manas Jaiswal of manasjaiswal.com recommends going long in Divis Laboratories at current level for a target of Rs 2600.

    • Like Divis Laboratories, Torrent Pharma: Anmol Ganjoo

      Anmol Ganjoo of JM Financial likes Divis Laboratories and Torrent Pharma from the pharma space.

    • Buy Divis Labs, Century Textiles: Manas Jaiswal

      Manas Jaiswal of manasjaiswal.com recommends buying Divis Laboratories and Century Textiles and Industries.

    • Positive on midcap pharma, including Divis Lab: Dipan Mehta

      Dipan Mehta, Member at BSE & NSE has a positive view on midcap pharma names including Divis Laboratories.

    • Top buzzing midcap stocks to trade on August 10

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have - PTC India Finance, MRPL, Vardhman Polytex, Divis Labs, GSPL, Ratnamani Metal, Marksans, Munjal Auto, SMS Pharma & Shakti Pumps.

    • Buy Divis Laboratories, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that traders may buy Divis Laboratories at current levels and then exit at some appropriate level.

    • Buy Divis Labs, go long in IRB Infra: Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Divis Laboratories and IRB Infrastructure Developers.

    • Divis Laboratories can reach Rs 2080, says Amit Gupta

      Amit Gupta of ICICIdirect is of the view that Divis Laboratories can reach Rs 2080.

    • Buy Divis Labs, create bull spread in Hexaware: VK Sharma

      VK Sharma of HDFC Securities recommends buying Divis Laboratories on dips at around Rs 22 and advises bull spread in Hexaware Technologies wherein one can buy 280 Call and sell the 290 Call.

    • Buy Divis Laboratories, says Amit Gupta

      Amit Gupta of ICICIdirect is of the view that one may buy Divis Laboratories and look for a target of Rs 2,080.

    • Buy Divis Laboratories, advises Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Divis Laboratories as the stock may test Rs 1950.

    • Phani Sekhar positive on largecap pharma space

      Phani Sekhar, Fund Manager--PMS at Karvy Stock Broking has a positive view on largecap pharma space.

    • Keep Divis Laboratories in portfolio: Amit Gupta

      Amit Gupta of ICICIdirect recommends keeping Divis Laboratories in the portfolio and feels that the stock may test Rs 2000.

    • Stay on long side in Divis Labs: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends staying on the long side in Divis Labs.

    • Remain invested in Divis Lab, says Gaurang Shah

      According to Gaurang Shah of Geojit BNP Paribas Financial Services, one may stay invested in Divis Laboratories.

    • Buy Infosys, Divis Laboratories, UPL: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Infosys, UPL and Divis Laboratories.

    • Go long in Divis Laboratories: Gaurav Bissa

      Gaurav Bissa, Derivatives Analyst at LKP Securities recommends going long in Divis Laboratories for a target of Rs 1840-1850.

    • Sell Divis Laboratories, Strides Arcolab: Manoj Murlidharan

      Manoj Murlidharan of Religare Securities recommends selling Divis Laboratories and Strides Arcolab.

    • See 10-15% upside in midcap pharma space: Vineet Bhatnagar

      Vineet Bhatnagar - MD at Phillip Capital expects 10-15 percent upside in midcap pharma stocks including Glenmark Pharma, Divis Laboratories, Torrent Pharma and Cadila Healthcare.

    • Go long in Divis Laboratories: Amit Gupta

      Amit Gupta of ICICIdirect recommends going long in Divis Laboratories.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347